Skip to main content

Prelude Therapeutics Inc

PRLD
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001678660

No open-market purchases or sales by Prelude Therapeutics Inc insiders were filed in the last 90 days; 75 institutions reported holding it in 13F filings for Q2 2026, worth $264.3M in total; no superinvestor holds it.

Q1 2025 vs. Q4 2024

How the institutions holding Prelude Therapeutics Inc changed between Q4 2024 and Q1 2025.

All holders in Q1 2025All holders in Q4 2024

13F holders of PRLD: Q4 2024 compared with Q1 2025
MeasureQ4 2024Of which not filed for Q1 2025Q1 2025Change
Holders62159−2
Shares32.2M16.8K30.5M−1.62M (−5.0%)
Value$41.0M$21.4K$23.3M−$17.7M (−43.2%)

1 institution that held it in Q4 2024 haven't filed for Q1 2025 yet. Not filing isn't selling, so the changes leave them out.

New holders (5)

Institutions that held Prelude Therapeutics Inc at the end of Q1 2025 but not at the end of Q4 2024.

Institutions new to PRLD in Q1 2025
InstitutionSharesValue% of portfolio
Marex Group plc56,270$43.2K0.00%
SG Americas Securities, LLC17,251$13.0K0.00%
True Wealth Design, LLC10$80.00%
EverSource Wealth Advisors, LLC9$70.00%
Nuveen, LLC187,613––

Sold out (7)

Institutions that held Prelude Therapeutics Inc at the end of Q4 2024 and filed for Q1 2025 without it.

Institutions that sold out of PRLD in Q1 2025
InstitutionShares, Q4 2024Value, Q4 2024
Jacobs Levy Equity Management, Inc666,574$849.9K
Massachusetts Financial Services Co494,497$630.5K
Marshall Wace, LLP392,155$498.0K
Exchange Traded Concepts, LLC64,409$82.1K
JustInvest LLC11,925$15.2K
Dimensional Fund Advisors LP10,981$13.9K
HighMark Wealth Management LLC50$64

Not filed for Q1 2025 yet (1)

Institutions that held Prelude Therapeutics Inc at the end of Q4 2024 and haven't filed a 13F for Q1 2025. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding PRLD in Q4 2024 that haven't filed for Q1 2025
InstitutionShares, Q4 2024Value, Q4 2024
Nuveen Asset Management, LLC16,797$21.4K